Clever Fundraising in UK for Lymphoma Research

UK cancer supporter James Barnard has come up with a unique way of raising money for charity as part of his London Marathon efforts.

Instead of turning to friends and family for sponsorship, James has turned to local business and website owners in an effort to raise money for the Lymphoma association. In return for a donation as little as £2, you’ll receive a piece of advertising space on the Sir Jog A Lot website. The more you donate, the higher up the page your donation is placed and the top 4 donations earn themselves a spot on every page on www.sirjogalot.com (now read by runners all over the globe).

James (25) is running the Virgin London Marathon 2010 in April for the Lymphoma Association. Take a look at his website by visiting www.sirjogalot.com/sponsor
If you’re a runner, you’ll enjoy browsing his site anyway, as he has plenty of advice for runners, both novice and veterans alike.

As you prepare for your own running events this spring, let me know if you attempt fundraising the same way, and we’ll promote your efforts as well.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap